openPR Logo
Press release

Antiobesity Global Market 2022-31 : Industry Analysis, Size, Share, Growth And Forecast | F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceuticals Company Limited

07-12-2022 08:13 AM CET | Health & Medicine

Press release from: The Business research company

Anti-obesity Drugs Market

Anti-obesity Drugs Market

The global antiobesity market size is expected to grow from $2.73 billion in 2021 to $3.08 billion in 2022 at a compound annual growth rate (CAGR) of 12.9%. The market growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-obesity market size is expected to reach $4.74 billion in 2026 at a CAGR of 11.4%.

The Business Research Company offers the Antiobesity Global Market Report 2022 in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market's historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.

Directly purchase the report here: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3403

The anti-obesity market consists of sales of anti-obesity drugs and related services. This industry includes establishments that produce pharmacological agents that reduce or control overweight.

Some key players anti-obesity market are F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd. and Novo Nordisk A/S.

The countries covered in the global antiobesity market are argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.

The regions covered in the global antiobesity market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Antiobesity Market Segmentation:
1) By Drug Class
Peripherally Acting Anti Obesity Drugs
Centrally Acting Anti Obesity Drugs

2) By Type
Prescription Drugs (Rx)
OTC Drugs

3) By Medication
Monotherapies
Polytherapies

See more on the report at https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

The Report's Table Of Contents includes
1. Executive Summary
2. Anti-obesity Drugs Market Characteristics
3. Anti-obesity Drugs Market Trends And Strategies
4. Impact Of COVID-19 On Anti-obesity Drugs
5. Anti-obesity Drugs Market Size And Growth
……
28. Anti-obesity Drugs Pipeline Analysis
29. Key Mergers And Acquisitions In The Anti-obesity Drugs Market
30. Anti-obesity Drugs Market Future Outlook and Potential Analysis
31. Appendix

This report covers the trends and market dynamics of the Antiobesity market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample of this report: https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Check out our blog: http://blog.tbrc.info/
And follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

About Us:
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. It has published over 3000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antiobesity Global Market 2022-31 : Industry Analysis, Size, Share, Growth And Forecast | F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceuticals Company Limited here

News-ID: 2676998 • Views: 324

More Releases from The Business research company

Avocado Market size and Forecast 2023-2032 | Industry overview, latest Trend and …
Avocado Market Size, Growth Rate, And Forecast: The global avocado market size is expected to grow from $13.81 billion in 2022 to $15 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge
Analysis Of Key Market Opportunities And Growth Trends In The Minimal Residual D …
The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 Minimal Residual Disease Testing Market Size, Growth Rate, And Forecast The global minimal residual disease testing market size is expected to grow from $1.22 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of
Global Methane Market Growth Prospects, Future Industry Landscape 2032 | BP Plc. …
The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 Methane Market Size, Growth Rate, And Forecast The global methane market size is expected to grow from $97.06 billion in 2022 to $106.65 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19
Jet Fuel Market 2023 Latest Insights, Growth Rate, Future Trends And Forecast | …
The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 Jet Fuel Market Size, Growth Rate, And Forecast The global jet fuel market size is expected to grow from $186.30 billion in 2022 to $195.98 billion in 2023 at a compound annual growth rate (CAGR) of 5.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug